These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32236631)

  • 1. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
    Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
    Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
    Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
    Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells.
    Chiu YJ; Tsai FJ; Bau DT; Chang LC; Hsieh MT; Lu CC; Kuo SC; Yang JS
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
    Han XL; Du J; Zheng YD; Dai JJ; Lin SW; Zhang BY; Zhong FB; Lin ZG; Jiang SQ; Wei W; Fang ZY
    Biomed Res Int; 2021; 2021():5089371. PubMed ID: 33959656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
    Kang J; Zhong Y; Tian W; Li J; Li X; Zhai L; Hou H; Li D
    Int J Oncol; 2021 May; 58(5):. PubMed ID: 33760108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.
    Wu J; Sun Z; Sun H; Li Y
    Mol Med Rep; 2018 Jan; 17(1):562-570. PubMed ID: 29115608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
    Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.
    Grieve S; Gao Y; Hall C; Hu J; Greer PA
    Mol Cell Biol; 2016 Aug; 36(15):2078-88. PubMed ID: 27215381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Ha GH; Kim DY; Breuer EK; Kim CK
    Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
    Zajac M; Gomez G; Benitez J; Martínez-Delgado B
    BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
    Zhao H; Yang Q; Hu Y; Zhang J
    Oncol Rep; 2018 Dec; 40(6):3223-3234. PubMed ID: 30272286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belinostat suppresses cell proliferation by inactivating Wnt/β-catenin pathway and promotes apoptosis through regulating PKC pathway in breast cancer.
    Lu P; Gu Y; Li L; Wang F; Yang X; Yang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3955-3960. PubMed ID: 31571495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
    Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
    Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
    Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.